Health Scope

Published by: Kowsar

Immunogenicity and Efficacy of Polytope DNA Vaccine Against Cutaneous Leishmaniosis In Vivo

Reza Keikha 1 , 2 , Mojgan Bandehpour 1 , 2 , Shabnam Jeibouei 1 , 2 and Bahram Kazemi 3 , *
Authors Information
1 Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Biotechnology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Parasitology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Health Scope: February 2018, 7 (1); e63159
  • Published Online: November 1, 2017
  • Article Type: Research Article
  • Received: August 1, 2016
  • Revised: November 28, 2016
  • Accepted: January 15, 2017
  • DOI: 10.5812/jhealthscope.63159

To Cite: Keikha R, Bandehpour M, Jeibouei S, Kazemi B. Immunogenicity and Efficacy of Polytope DNA Vaccine Against Cutaneous Leishmaniosis In Vivo, Health Scope. 2018 ;7(1):e63159. doi: 10.5812/jhealthscope.63159.

Abstract
© 2018, Journal of Health Scope. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
References
  • 1. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol. 2003;97 Suppl 1:3-15. doi: 10.1179/000349803225002499. [PubMed: 14678629].
  • 2. Savoia D. Recent updates and perspectives on leishmaniasis. J Infect Dev Ctries. 2015;9(6):588-96. doi: 10.3855/jidc.6833. [PubMed: 26142667].
  • 3. Chang P, Bray RS. Leishmaniasis. Elsevier Science Publishers BV (Biomedical Division); 1986.
  • 4. de Vries HJ, Reedijk SH, Schallig HD. Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol. 2015;16(2):99-109. doi: 10.1007/s40257-015-0114-z. [PubMed: 25687688].
  • 5. Hotez PJ, Savioli L, Fenwick A. Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis. 2012;6(2):1475. doi: 10.1371/journal.pntd.0001475. [PubMed: 22389729].
  • 6. Feiz Haddad MH, Ghasemi E, Maraghi S, Tavala M. Identification of Leishmania Species Isolated from Human Cutaneous Leishmaniasis in Mehran, Western Iran Using Nested PCR. Iran J Parasitol. 2016;11(1):65-72. [PubMed: 27095970].
  • 7. Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine. 2004;22(13-14):1631-9. doi: 10.1016/j.vaccine.2003.10.046. [PubMed: 15068845].
  • 8. Hosseini S, Hatam G, Ardehali S. Characterization of Leishmania isolated from unhealed lesions caused by leishmanization. East Mediterr Health J. 2005;11.
  • 9. Kedzierski L. Leishmaniasis Vaccine: Where are We Today? J Glob Infect Dis. 2010;2(2):177-85. doi: 10.4103/0974-777X.62881. [PubMed: 20606974].
  • 10. Khalil E, Hassan A, Zijlstra E, Mukhtar M, Ghalib H, Musa B, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan. Lancet. 2000;356(9241):1565-9.
  • 11. Murray HW. Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J Immunol. 2005;174(8):4916-23. [PubMed: 15814719].
  • 12. Gurunathan S, Stobie L, Prussin C, Sacks DL, Glaichenhaus N, Iwasaki A, et al. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol. 2000;165(2):915-24. [PubMed: 10878366].
  • 13. Campbell SA, Alawa J, Doro B, Henriquez FL, Roberts CW, Nok A, et al. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection. Vaccine. 2012;30(7):1357-63. doi: 10.1016/j.vaccine.2011.12.067. [PubMed: 22210224].
  • 14. Carrion J. Mechanisms of immunity to Leishmania major infection in mice: the contribution of DNA vaccines coding for two novel sets of histones (H2A-H2B or H3-H4). Comp Immunol Microbiol Infect Dis. 2011;34(5):381-6. doi: 10.1016/j.cimid.2011.06.002. [PubMed: 21840052].
  • 15. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Taslimi Y, Vahabpour R, et al. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release. 2011;153(2):154-62. doi: 10.1016/j.jconrel.2011.04.011. [PubMed: 21530597].
  • 16. Sanchez-Sampedro L, Gomez CE, Mejias-Perez E, Sorzano CO, Esteban M. High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection. PLoS One. 2012;7(6):38859. doi: 10.1371/journal.pone.0038859. [PubMed: 22715418].
  • 17. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol. 2000;18:927-74. doi: 10.1146/annurev.immunol.18.1.927. [PubMed: 10837079].
  • 18. Gurunathan S, Prussin C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med. 1998;4(12):1409-15. doi: 10.1038/4000. [PubMed: 9846579].
  • 19. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med. 1997;186(7):1137-47. [PubMed: 9314562].
  • 20. Stobie L, Gurunathan S, Prussin C, Sacks DL, Glaichenhaus N, Wu CY, et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci U S A. 2000;97(15):8427-32. doi: 10.1073/pnas.160197797. [PubMed: 10890924].
  • 21. Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther. 1998;9(13):1899-907. doi: 10.1089/hum.1998.9.13-1899. [PubMed: 9741428].
  • 22. Xu D, Liew FY. Genetic vaccination against leishmaniasis. Vaccine. 1994;12(16):1534-6. [PubMed: 7879420].
  • 23. Xu D, Liew FY. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology. 1995;84(2):173-6. [PubMed: 7750991].
  • 24. Handman E, Noormohammadi AH, Curtis JM, Baldwin T, Sjolander A. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine. 2000;18(26):3011-7. [PubMed: 10825604].
  • 25. Sukumaran B, Tewary P, Saxena S, Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine. 2003;21(11):1292-9.
  • 26. Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol. 2005;175(4):2517-24. [PubMed: 16081824].
  • 27. Sachdeva R, Banerjea AC, Malla N, Dubey ML. Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model. PLoS One. 2009;4(12):7880. doi: 10.1371/journal.pone.0007880. [PubMed: 19956549].
  • 28. Jeibouei SH, Bandehpour M, Kazemi B, Haghighi A. Designing a DNA Vaccine-based Leishmania major Polytope (Preliminary Report). Iran J Parasitol. 2017;12(3):441-5.
  • 29. Soong L, Chang CH, Sun J, Longley BJ, Ruddle NH, Flavell RA, et al. Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J Immunol. 1997;158(11):5374-83. [PubMed: 9164958].
  • 30. Wedrychowicz H. Antiparasitic DNA vaccines in 21st century. Acta Parasitol. 2015;60(2):179-89. doi: 10.1515/ap-2015-0026. [PubMed: 26203983].
  • 31. Bayih AG, Daifalla NS, Gedamu L. DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant. PLoS Negl Trop Dis. 2014;8(12):3391. doi: 10.1371/journal.pntd.0003391. [PubMed: 25500571].
  • 32. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2(4):251-62. doi: 10.1038/nri778. [PubMed: 12001996].
  • 33. Zaph C, Uzonna J, Beverley SM, Scott P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med. 2004;10(10):1104-10. doi: 10.1038/nm1108. [PubMed: 15448686].
  • 34. Uzonna JE, Wei G, Yurkowski D, Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol. 2001;167(12):6967-74. [PubMed: 11739516].

Altmetric:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Comments